Medicinal cannabis pastille manufacture, Bioxyne, delivered record revenue of more than A$14 million in the first […]
Bioxyne Posts Best-Ever Quarterly Revenue Despite Widening Cash Outflows
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
Related Articles
